Pamela Sauls, MD
Family Medicine · Perry, FLNPI 1184041741
Payments from drug & device makers
Across 119 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$992
- GSK$382
- Bayer$247
- AbbVie$144
- Sanofi-aventis U.S. LLC$137
- Lilly USA, LLC$136
- plus $749 from 15 others
What the payments were for
- Food & beverage$2,788100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $992 |
| GSK | 35 | $382 |
| Bayer | 8 | $247 |
| AbbVie | 8 | $144 |
| Sanofi-aventis U.S. LLC | 8 | $137 |
| Lilly USA, LLC | 8 | $136 |
| Boehringer Ingelheim | 7 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| Pfizer | 3 | $63 |
| Novo Nordisk | 4 | $58 |
| Amgen | 3 | $56 |
| Genentech USA, Inc. | 1 | $54 |
| GRT US Holding, Inc. | 1 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Abbott | 2 | $41 |
| Exact Sciences | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $29 |
| Medtronic | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,788 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $94,394 |
| JardianceEmpagliflozin | 56 | $69,842 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $69,678 |
| OzempicSemaglutide | 35 | $44,817 |
| LinzessLinaclotide | 27 | $31,132 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $25,955 |
| EntrestoSacubitril/Valsartan | 23 | $25,788 |
| FarxigaDapagliflozin Propanediol | 16 | $23,252 |
| TrulicityDulaglutide | 14 | $20,921 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $19,748 |
| TradjentaLinagliptin | 11 | $17,066 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $15,203 |
| DuleraMometasone/Formoterol | 39 | $14,149 |
| MyrbetriqMirabegron | 11 | $11,006 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 178 | $10,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $116 | $106,65683 claims |
| PfizerEliquis | $63 | $94,39468 claims |
| GSKTrelegy Ellipta | $382 | $69,67886 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $992 | $46,68450 claims |
| Novo NordiskOzempic | $58 | $44,81735 claims |
| AbbVieLinzess | $144 | $31,13227 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $137 | $25,95519 claims |
| Lilly USA, LLCTrulicity | $136 | $20,92114 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $11,00611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Perry
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.